The US Food and Drug Administration will no longer require premarket notifications for seven low-risk medical devices, and may stop requiring them for 83 more moderate-risk devices and an unclassified device.
The agency issued emergency guidance documents during the COVID-19 pandemic that temporarily suspended premarket notifications for a slew of class...






